Biorepository for liver disease samples
Virology, Immunology and Mechanisms of Liver Disease in Patients With Hepatitis C and Other Liver Diseases
This study is collecting samples from patients with liver diseases to help researchers find better treatments and improve care for these conditions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 7 Years and up |
| Sex | All |
| Sponsor | State University of New York at Buffalo Academic / other |
| Locations | 1 site (Buffalo, New York) |
| Trial ID | NCT03025074 on ClinicalTrials.gov |
What this trial studies
This biorepository at the University at Buffalo aims to collect high-quality biological samples from patients with various liver diseases, including Non-Alcoholic Steatohepatitis (NASH), Hepatitis C, and Hepatitis B. The initiative is designed to foster collaboration between clinicians and researchers, enhance training for junior investigators, and promote multidisciplinary approaches in translational medicine. By providing these specimens, the biorepository supports research efforts aimed at discovering new treatments and improving patient care for liver diseases. The goal is to create a comprehensive resource of clinically annotated samples from patients in Western New York.
Who should consider this trial
Good fit: Ideal candidates include individuals with liver diseases such as NASH, Hepatitis C, and Hepatitis B, as well as healthy controls.
Not a fit: Patients who are unable to consent, including infants, pregnant women, and prisoners, will not benefit from this study.
Why it matters
Potential benefit: If successful, this biorepository could significantly advance research and treatment options for patients suffering from liver diseases.
How similar studies have performed: Other biorepositories focused on liver diseases have shown success in advancing research, making this approach both valuable and tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * This protocol is to establish a biobank of blood samples from individuals with or without liver diseases including viral hepatitis, liver cancer, NASH, and negative control samples. * Children and teenagers will be special populations considered in this protocol. Exclusion Criteria: * Vulnerable populations such as adults unable to consent, infants, pregnant women or prisoners will not be considered for this research study.
Where this trial is running
Buffalo, New York
- University at Buffalo, Buffalo General Medical Center — Buffalo, New York, United States (Recruiting)
Study contacts
- Principal investigator: Andrew Talal, MD — University at Buffalo
- Study coordinator: Barbara Bauer, BA
- Email: bmbauer@buffalo.edu
- Phone: 716-888-4825
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.